ICU Medical, Inc. (ICUI) – What Are Researchers Thinking About This Stock?

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have received an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, four have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $192.80.

Several equities research analysts recently weighed in on ICUI shares. Needham & Company LLC upped their price target on ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Zacks Research cut shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. BTIG Research upped their target price on shares of ICU Medical from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Piper Sandler increased their price target on shares of ICU Medical from $163.00 to $195.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, KeyCorp lifted their price target on shares of ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a research report on Tuesday, July 21st.

ICU Medical Stock Up 1.4%

Shares of NASDAQ:ICUI opened at $168.65 on Friday. The firm has a fifty day moving average price of $164.60 and a two-hundred day moving average price of $148.83. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. ICU Medical has a one year low of $113.37 and a one year high of $192.85. The company has a market cap of $4.21 billion, a price-to-earnings ratio of 142.92, a PEG ratio of 2.09 and a beta of 0.86.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The company had revenue of $547.88 million during the quarter, compared to analyst estimates of $533.44 million. During the same period in the previous year, the business earned $2.10 earnings per share. The firm’s quarterly revenue was up .5% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Analysts anticipate that ICU Medical will post 7.22 EPS for the current fiscal year.

Insider Buying and Selling

In other ICU Medical news, VP Virginia Sanzone sold 4,856 shares of ICU Medical stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $168.69, for a total value of $819,158.64. Following the completion of the sale, the vice president owned 14,604 shares of the company’s stock, valued at approximately $2,463,548.76. The trade was a 24.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Christian B. Voigtlander sold 8,929 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $182.93, for a total transaction of $1,633,381.97. Following the completion of the transaction, the chief operating officer owned 37,377 shares in the company, valued at $6,837,374.61. This trade represents a 19.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 21,830 shares of company stock worth $3,905,003 in the last three months. 2.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Allworth Financial LP purchased a new stake in shares of ICU Medical in the second quarter valued at approximately $26,000. Versant Capital Management Inc increased its holdings in ICU Medical by 26.2% during the 3rd quarter. Versant Capital Management Inc now owns 313 shares of the medical instruments supplier’s stock worth $50,000 after purchasing an additional 65 shares during the period. Public Employees Retirement System of Ohio bought a new stake in ICU Medical during the 2nd quarter valued at $51,000. Rockefeller Capital Management L.P. lifted its holdings in shares of ICU Medical by 21.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock worth $117,000 after buying an additional 146 shares during the period. Finally, Nykredit A S purchased a new stake in shares of ICU Medical in the 2nd quarter worth $135,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.

The company’s portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.

Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira’s infusion systems business in 2017 and Smiths Medical in 2022.